Literature DB >> 16728286

Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: synergism with veto cells and rapamycin.

David Steiner1, Noga Brunicki, Esther Bachar-Lustig, Patricia A Taylor, Bruce R Blazar, Yair Reisner.   

Abstract

Recently, we have shown that anti-third-party cytotoxic T lymphocytes (CTLs) depleted of alloreactivity against the host are endowed with marked veto activity and can facilitate bone marrow (BM) allografting without graft-versus-host disease. We also demonstrated synergism between rapamycin (RAPA) and the veto cells. CD4(+)CD25(+) T-regulatory (Treg) cells are suppressor cells that can enhance alloengraftment. We investigated whether donor Tregs would be synergistic with veto CTLs and RAPA in augmenting alloengraftment or, conversely, would suppress veto CTL effects. Lethally irradiated C3H mice were transplanted at day 2 after irradiation with Balb-nude BM. Graft rejection was induced by purified host-type T cells infused 1 day prior to BMT. The addition of Tregs led to moderate enhancement of engraftment. RAPA at different doses was synergistic with Tregs. The addition of veto CTLs to Tregs enabled reducing the effective RAPA dose fourfold. Combining all three agents was necessary to overcome rejection at low-dose RAPA. Chimerism analysis at 5 to 9 months revealed a significant presence of host-type cells coexisting with the predominant donor T cells, suggesting that tolerance had been attained. The synergistic effects between Tregs, veto CTLs, and RAPA offer an attractive approach for facilitating alloengraftment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728286     DOI: 10.1016/j.exphem.2006.02.017

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

1.  Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus.

Authors:  K Singh; N Kozyr; L Stempora; A D Kirk; C P Larsen; B R Blazar; L S Kean
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

Review 2.  Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy.

Authors:  Robert Zeiser; Robert S Negrin
Journal:  Cell Cycle       Date:  2007-12-18       Impact factor: 4.534

3.  Allogeneic T regulatory cell-mediated transplantation tolerance in adoptive therapy depends on dominant peripheral suppression and central tolerance.

Authors:  Dennis Adeegbe; Robert B Levy; Thomas R Malek
Journal:  Blood       Date:  2009-12-29       Impact factor: 22.113

4.  Expanded nonhuman primate tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses.

Authors:  A Anderson; C L Martens; R Hendrix; L L Stempora; W P Miller; K Hamby; M Russell; E Strobert; B R Blazar; T C Pearson; C P Larsen; L S Kean
Journal:  Am J Transplant       Date:  2008-09-17       Impact factor: 8.086

5.  T regulatory cell mediated immunotherapy for solid organ transplantation: A clinical perspective.

Authors:  Mohammad Afzal Khan
Journal:  Mol Med       Date:  2016-11-22       Impact factor: 6.354

6.  Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory T cells while inhibiting conventional T cells.

Authors:  Atsushi Satake; Amanda M Schmidt; Angela Archambault; Theresa M Leichner; Gregory F Wu; Taku Kambayashi
Journal:  J Autoimmun       Date:  2013-07-05       Impact factor: 7.094

Review 7.  Therapeutic use of regulatory T cells for graft-versus-host disease.

Authors:  Shlomo Elias; Alexander Y Rudensky
Journal:  Br J Haematol       Date:  2019-08-16       Impact factor: 6.998

8.  In situ activation and expansion of host tregs: a new approach to enhance donor chimerism and stable engraftment in major histocompatibility complex-matched allogeneic hematopoietic cell transplantation.

Authors:  Alwi Shatry; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2009-05-07       Impact factor: 5.742

9.  Hematopoietic stem cell transplantation across major genetic barriers.

Authors:  Yair Reisner
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.

Authors:  Robert Zeiser; Dennis B Leveson-Gower; Elizabeth A Zambricki; Neeraja Kambham; Andreas Beilhack; John Loh; Jing-Zhou Hou; Robert S Negrin
Journal:  Blood       Date:  2007-10-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.